Author:
Kobayashi Hiroaki,Wake Norio
Reference13 articles.
1. Ovarian Cancer Treatment Guidelines 2007 (in Japanese). Japan Society of Gynecologic Oncology.
http://www.jsgo.gr.jp/09_guideline/guideline/ransou2007-02.pdf
.
2. Kamura T, Tsukamoto N, Suenaga T, Kaku T, Matsukuma K, Matsuyama T. Evaluation of the efficacy of cisplatin-based chemotherapy for epithelial ovarian cancer: comparison with treatments employed before cisplatin era (in Japanese). Gan To Kagaku Ryoho. 1987;14:1260–3.
3. Kuzuya K, Ishikawa H, Nakanishi T, et al. Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study. Int J Clin Oncol. 2001;6:271–8.
4. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1303–5.
5. Sugiyama T, Yakushiji M, Kamura T, et al. Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology. 2002;63:16–22.